Rating Rationale
June 29, 2022 | Mumbai
Nitta Gelatin India Limited
Ratings reaffirmed at 'CRISIL A- / Stable / CRISIL A2+ '; rated amount enhanced for Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.103.9 Crore (Enhanced from Rs.91.21 Crore)
Long Term RatingCRISIL A-/Stable (Reaffirmed)
Short Term RatingCRISIL A2+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL A-/Stable/CRISIL A2+’ ratings on the bank facilities of Nitta Gelatin India Ltd (NGIL; part of the NGIL group).

 

The NGIL group saw revenue growth of 29% in fiscal 2022, due to higher realisations on products such as collagen peptide and ossein, and increase in overall sales volume. This, along with better fixed cost absorption, led to rise in operating profit to Rs 68 crore in fiscal 2022 from Rs 48 crore in fiscal 2021. With customers becoming more conscious about health and immunity, demand for gelatin and other protein-based products should remain healthy. However, operating margin may be restricted to 11-12% in the medium term, owing to a rise in input prices, especially crushed bones, following a demand-supply mismatch. Furthermore, as the group is operating at peak capacity, revenue growth will be restricted until it expands capacity.

 

The financial risk profile and liquidity are likely to remain healthy, driven by cash accrual of over Rs 35 crore per fiscal against capital expenditure (capex) of around Rs 18 crore and negligible long-term debt in fiscal 2023,. Gearing was below 0.45 time as on March 31, 2022, while debt protection metrics remained healthy, with interest coverage and net cash accrual to total debt (NCATD) ratios over 14 times and 0.55 time, respectively, for fiscal 2022.

 

The ratings continue to reflect the established position of the NGIL group in the gelatin industry, steady support from joint venture (JV) partner, Nitta Gelatin Inc, Japan (NGI), and strong financial risk profile. These strengths are partially offset by susceptibility to fluctuations in input prices and foreign exchange (forex) rates, and probability of disruption of operations or sub-optimal capacity utilisation due to pollution concerns.

Analytical Approach

CRISIL Ratings has combined the financial and business risk profiles of NGIL and its subsidiary, Bamni Proteins Ltd (BPL). This is because the two companies, collectively referred to as the NGIL group, are in the same business, operate under a common management and have significant operational and financial synergies.

 

NGIL has redeemable preference shares of Rs 3.8 crore as consideration towards NGI’s stake in Reva. Considering the redeemable and interest-bearing nature of these shares, CRISIL Ratings has treated the same as debt.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

Established presence in the gelatin market with recognised brand, and steady support from NGI: The group is a strong player in the gelatin market. It started producing ossein and di-calcium phosphate (DCP) in 1978, and gelatin in 1999. It has a technological tie-up and operational linkages with Osaka-based NGI (which holds 43% stake in NGIL), a leading gelatin manufacturer in the world, and enjoys considerable brand equity.

 

Adequate financial risk profile: Debt protection metrics were healthy, with interest coverage and NCATD ratios of over 14 times and 0.55 time, respectively, in fiscal 2022 (8.5 times and 0.38 time, respectively, in 2021). Gearing was below 0.45 time as on March 31, 2022. Given the moderate capex, steady cash accrual and progressive debt repayment, the financial risk profile should remain strong over the medium term.

 

Weaknesses:

Susceptibility to volatility in input prices and forex rates: Crushed animal (cattle) bone and hydrochloric acid are the key raw materials for the NGIL group. The market for crushed animal bone is highly unorganised and keeps the operating margin susceptible to price hikes. Supply of crushed bones was disrupted during the Covid-19 pandemic and has not normalised yet. Additionally, the group has sizeable forex exposure because of exports. Although 60% of export receivables are hedged using forward contracts, the group remains vulnerable to any steep fluctuation in forex rates.

 

Exposure to concerns over pollution norms: Operations of NGIL have been disrupted at its ossein plant in Koratty, Kerala, due to an agitation pertaining to the alleged pollution due to effluents discharged by the plant. While NGIL has taken various measures such as construction of an anaerobic digester (to be operational by September 2022) to address these concerns, the pollution allegation case is pending before the High Court of Kerala. Operations will remain susceptible to similar protests and any stringent pollution control requirements hereon.

Liquidity: Adequate

Cash accrual is expected over Rs 35 crore each in fiscals 2023 and 2024. Utilisation of the fund-based limit of Rs 83 crore was moderate, at 58% on average in the 13 months ended April 30, 2022. Planned capex of around Rs 18 crore in fiscal 2023, along with negligible debt obligation and incremental working capital expenses, should be covered through internal accrual and cushion in the bank limit.

Outlook: Stable

The NGIL group will continue to benefit from its established position in the domestic gelatin market, support from NGI, and its adequate financial risk profile.

Rating Sensitivity factors

Upward factors

  • Sustained revenue growth of 12-15% or more and steady operating margin of over 12%
  • Improvement in gearing and debt protection metrics

 

Downward factors

  • Decline in revenue by over 20% or in operating margin below 8%
  • Change in stance of support from NGI
  • Major debt-funded capex weakening credit metrics
  • Operational disruptions due to perceived environmental concerns, agitations or court verdicts on pollution control

About the Group

Set up in 1975, NGIL is a JV between the Kerala State Industrial Development Corporation (32% shareholding) and NGI (43%). The company manufactures gelatin, ossein, limed ossein, and DCP by processing crushed animal bone and treating it with hydrochloric acid. It also produces collagen peptide-based consumer products used in the pharmaceuticals and healthcare industries. BPL processes crushed animal bone and hydrochloric acid into ossein and supplies to NGIL.

 

NGIL merged its erstwhile subsidiary, Reva, with itself with effect from April 1, 2017, after receipt of approval from the National Company Law Tribunal in fiscal 2019.

Key Financial Indicators

Particulars

Unit

2022

2021

Operating Income

Rs crore

506

396

Profit after tax (PAT)

Rs crore

35

18

PAT margin

%

6.9

4.5

Adjusted debt/ adjusted networth

Times

0.42

0.46

Interest coverage

Times

14.27

8.46

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs crore)

Complexity

levels

Rating

NA

Bill purchase-discounting facility

NA

NA

NA

28.3

NA

CRISIL A2+

NA

Cash credit

NA

NA

NA

11

NA

CRISIL A-/Stable

NA

Letter of credit & bank guarantee

NA

NA

NA

4.6

NA

CRISIL A2+

NA

Packing credit

NA

NA

NA

54

NA

CRISIL A2+

NA

Term Loan

NA

NA

31-Mar-26

6

NA

CRISIL A-/Stable

Annexure – List of entities consolidated

Names of Entities Consolidated

Extent of Consolidation

Rationale for Consolidation

Nitta Gelatin India Limited

Full

Subsidiary, business synergies

Reva Proteins Limited

Full

Subsidiary, business synergies

Bamni Proteins Limited

Full

Subsidiary, business synergies

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 99.3 CRISIL A2+ / CRISIL A-/Stable 02-06-22 CRISIL A2+ / CRISIL A-/Stable 03-09-21 CRISIL A2+ / CRISIL A-/Stable 23-07-20 CRISIL A2+ / CRISIL A-/Stable 08-04-19 CRISIL A2+ / CRISIL A-/Negative CRISIL A2+ / CRISIL A-/Negative
      --   --   -- 06-03-20 CRISIL A2+ / CRISIL A-/Stable 22-03-19 CRISIL A2+ / CRISIL A-/Negative CRISIL A-/Negative
Non-Fund Based Facilities ST 4.6 CRISIL A2+ 02-06-22 CRISIL A2+ 03-09-21 CRISIL A2+ 23-07-20 CRISIL A2+ 08-04-19 CRISIL A2+ CRISIL A2+
      --   --   -- 06-03-20 CRISIL A2+ 22-03-19 CRISIL A2+ --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bill Purchase-Discounting Facility 5 Standard Chartered Bank Limited CRISIL A2+
Bill Purchase-Discounting Facility 2.69 State Bank of India CRISIL A2+
Bill Purchase-Discounting Facility 17.61 State Bank of India CRISIL A2+
Bill Purchase-Discounting Facility 3 HDFC Bank Limited CRISIL A2+
Cash Credit 6 HDFC Bank Limited CRISIL A-/Stable
Cash Credit 5 State Bank of India CRISIL A-/Stable
Letter of credit & Bank Guarantee 4.6 State Bank of India CRISIL A2+
Packing Credit 5 Standard Chartered Bank Limited CRISIL A2+
Packing Credit 16 Sumitomo Mitsui Banking Corporation CRISIL A2+
Packing Credit 20 State Bank of India CRISIL A2+
Packing Credit 3 HDFC Bank Limited CRISIL A2+
Packing Credit 10 Mizuho Bank Limited CRISIL A2+
Term Loan 6 State Bank of India CRISIL A-/Stable

This Annexure has been updated on 29-Jun-2022 in line with the lender-wise facility details as on 2-Sep-2021 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
D:+91 44 6656 3100
anuj.sethi@crisil.com


Aditya Jhaver
Director
CRISIL Ratings Limited
D:+91 22 3342 3000
Aditya.Jhaver@crisil.com


Vedant Haldekar
Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Vedant.Haldekar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html